- Home
- OUSTZ vs SNGX Comparison
OUSTZ vs SNGX Comparison
Compare OUSTZ & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUSTZ
- SNGX
- Stock Information
- Founded
- OUSTZ N/A
- SNGX 1987
- Country
- OUSTZ United States
- SNGX United States
- Employees
- OUSTZ 290
- SNGX N/A
- Industry
- OUSTZ Industrial Machinery/Components
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- OUSTZ Industrials
- SNGX Health Care
- Exchange
- OUSTZ Nasdaq
- SNGX Nasdaq
- Market Cap
- OUSTZ N/A
- SNGX 7.4M
- IPO Year
- OUSTZ N/A
- SNGX 1987
- Fundamental
- Price
- OUSTZ $0.08
- SNGX $2.31
- Analyst Decision
- OUSTZ
- SNGX
- Analyst Count
- OUSTZ 0
- SNGX 0
- Target Price
- OUSTZ N/A
- SNGX N/A
- AVG Volume (30 Days)
- OUSTZ N/A
- SNGX 623.6K
- Earning Date
- OUSTZ N/A
- SNGX 03-14-2025
- Dividend Yield
- OUSTZ N/A
- SNGX N/A
- EPS Growth
- OUSTZ N/A
- SNGX N/A
- EPS
- OUSTZ N/A
- SNGX N/A
- Revenue
- OUSTZ N/A
- SNGX $364,183.00
- Revenue This Year
- OUSTZ N/A
- SNGX N/A
- Revenue Next Year
- OUSTZ N/A
- SNGX $76.64
- P/E Ratio
- OUSTZ N/A
- SNGX N/A
- Revenue Growth
- OUSTZ N/A
- SNGX N/A
- 52 Week Low
- OUSTZ N/A
- SNGX $1.83
- 52 Week High
- OUSTZ N/A
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- OUSTZ N/A
- SNGX 34.85
- Support Level
- OUSTZ N/A
- SNGX $2.33
- Resistance Level
- OUSTZ N/A
- SNGX $2.63
- Average True Range (ATR)
- OUSTZ 0.00
- SNGX 0.25
- MACD
- OUSTZ 0.00
- SNGX -0.01
- Stochastic Oscillator
- OUSTZ 0.00
- SNGX 17.73
About OUSTZ Ouster Inc. Warrants
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).